A Programme for Risk Assessment and Minimisation of Progressive Multifocal Leukoencephalopathy Developed for Vedolizumab Clinical Trials. [electronic resource]
Producer: 20181106Description: 807-816 p. digitalISSN:- 1179-1942
- Antibodies, Monoclonal, Humanized -- adverse effects
- Clinical Trials, Phase II as Topic -- methods
- Clinical Trials, Phase III as Topic -- methods
- Gastrointestinal Agents -- adverse effects
- Humans
- Inflammatory Bowel Diseases -- drug therapy
- Leukoencephalopathy, Progressive Multifocal -- chemically induced
- Multicenter Studies as Topic -- methods
- Randomized Controlled Trials as Topic -- methods
- Risk Assessment -- methods
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.